Clinical Trials · NCT03573908

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Name: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Linaclotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ironwood Pharmaceuticals, Inc.
Enrollment: 614
Start date: Jun 2018
Locations: 79 sites, United States
Primary endpoint: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period

View Linaclotide compound reference